Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Director | November 05, 2019 | November 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date November 05, 2019 · Filed November 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2029-11-05 | Direct | 100,000 |
Reported balance
After 2019-11-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-05 · Grant · Acquired 100,000 · Balance 100,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 05, 2019 Filed Nov 7, 2019 21:12 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001596771-19-000132 · primary_doc.xml · derivative · entry 1 Kalia Suraj · CIK 0001709984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-11-05 Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:54 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 14,995 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001596771-19-000061 · primary_doc.xml · derivative · entry 2 Kalia Suraj · CIK 0001709984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,995 Underlying: Common Stock · 14,995 shares Expires 2029-06-04 F2 · derivative.exercise_date: Vests in 12 approximately equal consecutive monthly increments, commencing on the one-month anniversary of the date of grant, so that all of the options will be vested on the one-year anniversary of the date of grant. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:54 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 14,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-19-000061 · primary_doc.xml · nonDerivative · entry 1 Kalia Suraj · CIK 0001709984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,006 F1 · shares: Represents a grant of restricted stock units. Vests in 12 approximately equal consecutive monthly increments, commencing on the one-month anniversary of the date of grant, so that all of the shares will be vested on the one-year anniversary of the date of grant. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:23 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 45,605 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001596771-19-000043 · primary_doc.xml · derivative · entry 1 Kalia Suraj · CIK 0001709984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,605 Underlying: Common Stock · 45,605 shares Expires 2029-05-13 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.